CAS: 4480-83-5; Diglycolicanhydride

相似化合物

502-97-6 19500-95-9 57321-93-4

上下游产品

2,2'-oxybis-acetic acid{2-[4-(3-chloro-4-methyl-phenyl)-piperazino]-2-oxo-ethoxy}-acetic acid (phenylcarbamoyl-methoxy)-acetic acid benzothiazol-2-ylmethoxy-acetic acid maleic anhydride

二甘醇酸置于三氟乙酸酐体系中,用 乙酸乙酯 作为反应溶剂,化学反应 24.0H,以84%的收率获得产物二甘醇酐
参考文献:Castagnoli-Cushman三组分反应的新杂环产物空间
标题:Castagnoli-Cushman三组分反应的新杂环产物空间
摘要:通过使用含有氧,氮和硫的内环取代的戊二酸酐类似物,已经实现了castagnoli-Cushman反应(ccr)可访问的杂环产物空间的显着扩展.将这些杂原子掺入酸酐的主链中可提高反应活性,并通常降低反应完成所需的温度.鉴于最近被认为是铅导向合成的有效工具的ccr,这些发现尤其重要.
DOI:10.1021/acs.Orglett.5B02014

专利信息

专利号:US-2004152905-A1
优先权日:2003-01-31
标题:Universal building blocks and support media for synthesis of oligonucleotides and their analogs
发明人：GUZAEV ANDREI P; MANOHARAN MUTHIAH
摘要:Compounds for the synthesis of oligomeric compounds, particularly oligonucleotides and chemically modified oligonucleotide analogs, are provided. In addition, methods for functionalization of a support medium with a first monomeric subunit and methods for the synthesis of oligomeric compounds utilizing the novel compounds bound to support media are provided.

专利号:US-8415510-B2
优先权日:2008-02-28
标题 :Synthesis of a PEG-6 moiety from commercial low-cost chemicals
发明人：ENGELL TORGRIM
权利人:ENGELL TORGRIM; GE HEALTHCARE LTD
摘要:The present invention provides novel synthesis's for obtaining a protecting group aminoxy PEG-6 linker from cost effective, and readily available starting materials and chemicals or modified polyethylene glycols. More specifically, a novel synthesis of obtaining a modified Boc-protected aminoxy PEG-6 linker was achieved so that said linker may be attached to a vector such as a peptide based fragment.

专利号:US-8536375-B2
优先权日:2008-12-22
标题:Synthesis of obtaining modified polyethylene glycol intermediates
发明人：ENGELL TORGRIM
权利人:ENGELL TORGRIM; GE HEALTHCARE LTD
摘要:The present invention provides novel and more efficient synthesis's for obtaining an intermediate in the synthesis of obtaining a protecting group aminoxy PEG linker.

专利号:US-6159673-A
优先权日:1996-07-17
标 题:Oxonol compound, light-sensitive material and process for the synthesis of oxonol compound
发明人：NISHIGAKI JUNJI; DEGUCHI YASUAKI
权利人:FUJI PHOTO FILM CO LTD
摘要:An oxonol compound is represented by the following formula (I): in which Z is an atomic group that forms a cyclic amide ring; each of W1 and W2 independently is an atomic group that forms an acidic nucleus ring; and M is a cation. Other oxonol compounds, a light-sensitive material containing an oxonol compound and a process for the synthesis of an oxonol compound are also disclosed.

专利号:US-8519184-B2
优先权日:2010-07-05
标 题:Synthesis of rare earth metal extractant
发明人：SAKAKI KAZUAKI; SUGAHARA HIROTO; OHASHI TETSUYA; KUME TETSUYA; IKKA MASAHIKO; NAGANAWA HIROCHIKA; SHIMOJO KOJIRO
权利人:SAKAKI KAZUAKI; SUGAHARA HIROTO; OHASHI TETSUYA; KUME TETSUYA; IKKA MASAHIKO; NAGANAWA HIROCHIKA; SHIMOJO KOJIRO; SHINETSU CHEMICAL CO; NISSIN CHEMICAL IND
摘要:A rare earth metal extractant in the form of a dialkyl diglycol amic acid is synthesized by reacting diglycolic anhydride with a dialkylamine in a synthesis medium. A molar ratio (B/A) of dialkylamine (B) to diglycolic anhydride (A) is at least 1.0. A non-polar or low-polar solvent in which the dialkyl diglycol amic acid is dissolvable is used as the synthesis medium.

专利号:US-6469065-B1
优先权日:1996-02-02
标 题:Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
发明人：GARVEY DAVID S; SCHROEDER JOSEPH D; DE TEJADA INIGO SAENEZ; GASTON RICKY D; SHELEKHIN TATIANA E; WANG TIANSHENG
权利人:NITROMED INC
摘要:The present invention describes novel nitrosated and/or nitrosylated α-adrenergic receptor antagonists, and novel compositions containing at least one nitrosated and/or nitrosylated α-adrenergic receptor antagonist, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are a substrate for nitric oxide synthase, and/or one or more vasoactive agents. The present invention also provides novel compositions containing at least one α-adrenergic receptor antagonist, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing benign prostatic hyperplasia, hypertension, congestive heart failure, variant (Printzmetal) angina, glaucoma, neurodegenerative disorders, vasospastic diseases, cognitive disorders, urge incontinence, or overactive bladder, and for reversing the state of anesthesia.